An observational study in Cushing's Syndrome, sponsored by Corcept Therapeutics. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-06-01.
Sponsored by Corcept Therapeutics · Observational
Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome.
A retrospective, multi-center, chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome. Treatment with Korlym® will be a minimum 3 months in duration with follow-up of a minimum 3 months. Only sites that have been identified to have patients appropriate for this protocol will be invited to participate.
123 studies on the registry are indexed under Cushing Syndrome; 37 are open to participants now.
This study's enrollment of 24 is below the median of 115 across 62 observational studies indexed under Cushing Syndrome.
Browse Cushing Syndrome studies →Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 4 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 9 (29%) have results posted.
Counted across the registry records on this site, refreshed daily.
ACTH Independent Cushing's Syndrome patients treated with Korlym® mifepristone) as standard of care in clinical practice.
Exclusion Criteria:
No treatment (intervention) was administered.
Drug Utilization Patterns as assessed by chart review
The retrospective review would analyze the drug utilization patterns of patients treated with Korlym
Time frame: up to 4 years
Clinical Outcomes as assessed by chart review
The retrospective review would analyze outcomes measures (vitals, clinical assessments, etc) in patients treated with Korlym
Time frame: up to 4 years
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Corcept Therapeutics